In recent years, ICIs have transformed cancer treatment by harnessing the body’s immune system to target and destroy cancer cells (1–3). ICIs work by blocking inhibitory signals that prevent T cells from attacking tumors, thereby reactivating the immune response against cancer. The most common targets for these therapies are the PD-1/PD-L1 and CTLA-4 pathways, which are critical in regulating immune responses (4). For example, nivolumab, a PD - 1 inhibitor, has been a breakthrough in the treatment of melanoma. In a large - scale clinical trial involving patients with advanced melanoma, nivolumab treatment led to a significant improvement in overall survival, with approximately 40% of patients surviving for more than five years compared to less than 20% with traditional chemotherapy (5). Pembrolizumab, another PD - 1 inhibitor, has shown remarkable efficacy in non - small cell lung cancer (NSCLC). In a phase III trial, it demonstrated an objective response rate of around 20% - 30% in previously treated patients and has since been incorporated into first - line treatment regimens, improving survival outcomes and quality of life for many patients (6). Ipilimumab, a CTLA - 4 inhibitor, has had a transformative impact on metastatic melanoma. It was the first drug to show an overall survival benefit in this difficult - to - treat cancer, increasing the median survival time by several months and providing a new treatment option for patients with limited alternatives (7, 8). These examples clearly illustrate the remarkable success of ICIs in different cancer types and their ability to revolutionize cancer treatment. While ICIs have demonstrated efficacy in a range of cancers, including melanoma and non - small cell lung cancer, their potential in treating bone tumors remains underexplored. Addressing this gap, the article also considers strategies tailored to enhance ICI efficacy specifically in bone tumor cases.

These therapies have been particularly revolutionary for cancers that were previously difficult to treat, offering the potential for long-term remission in some patients. However, despite these successes, ICIs are not universally effective. Many patients do not respond to treatment, and those who do may develop resistance over time (9). Additionally, the activation of the immune system can lead to severe immune-related adverse events (irAEs), which can affect various organs and require careful management (10). The challenges of suboptimal efficacy and significant toxicity highlight the need for refined strategies in the use of ICIs. Personalized approaches, combination therapies, and the development of next-generation ICIs with improved specificity and safety profiles are essential to maximizing the therapeutic potential of these treatments.

Despite the transformative potential of ICIs, their use is accompanied by significant challenges. One of the foremost issues is the variable response among patients. While some individuals experience dramatic and long-lasting tumor regression, many others do not respond to ICIs at all, a phenomenon known as primary resistance (10). Even among responders, a subset may develop acquired resistance over time, leading to cancer progression after an initial period of remission (11).

Another critical challenge is the occurrence of irAEs. These toxicities arise from the over activation of the immune system and can affect multiple organs, including the skin, gastrointestinal tract, liver, and endocrine system (12). IrAEs range from mild to severe and can be life-threatening, necessitating the use of immunosuppressive treatments that might diminish the anti-tumor efficacy of ICIs (13). Additionally, the phenomenon of resistance is a major hurdle. Primary resistance, where patients do not respond to ICIs from the start, may be attributed to several factors. Tumors with low immunogenicity, due to a lack of tumor - specific antigens or a suppressive tumor microenvironment rich in immunosuppressive cells like regulatory T cells (Tregs) and myeloid - derived suppressor cells (MDSCs), can prevent effective T cell activation and infiltration (14). Genetic alterations within the tumor cells, such as mutations in the interferon - gamma pathway genes, can also lead to primary resistance (15). Acquired resistance, which develops over time in initially responsive patients, may involve the upregulation of alternative immune checkpoint pathways, such as TIM - 3 and LAG - 3, that compensate for the blocked PD - 1/PD - L1 or CTLA - 4 pathways (16). Tumor cells can also adapt by losing expression of target antigens or developing mechanisms to evade immune recognition, such as through antigen - presentation machinery defects (17). Understanding these mechanisms underlying resistance is crucial as it sets the stage for the later discussion on emerging strategies to overcome resistance. Furthermore, the high cost of ICIs presents a significant barrier to access, limiting their availability to a broader patient population (18). These challenges underscore the urgent need for strategies to predict response, manage toxicity, and reduce costs, thereby optimizing the clinical application of ICIs in cancer therapy.

ICIs targeting the PD-1/PD-L1 and CTLA-4 pathways have become integral to modern cancer therapy (19, 20). PD-1 inhibitors, such as nivolumab and pembrolizumab, prevent the interaction between PD-1 on T cells and its ligand PD-L1 on tumor cells, thereby reinvigorating T cells to attack cancer (21). These inhibitors have shown substantial efficacy in treating various cancers, including melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma. Similarly, CTLA-4 inhibitors like ipilimumab enhance T cell activation by blocking the inhibitory signals that dampen immune responses, particularly in the context of metastatic melanoma (22).

Despite these successes, not all patients benefit from these therapies. Response rates vary significantly, with some tumors being more resistant due to various factors, including the tumor microenvironment and genetic mutations (23). Bone tumors, particularly osteosarcoma, present unique challenges in immunotherapy due to their complex microenvironment (24). This article explores how tailored approaches could potentially overcome these barriers, leading to improved outcomes in bone tumor patients. Additionally, while ICIs have transformed the outlook for many patients, they are not curative for all, and a significant portion of patients eventually develop resistance (25). These limitations highlight the need for ongoing research to refine these treatments and develop new strategies to overcome resistance and improve response rates.

The introduction of ICIs has marked a significant advancement in cancer therapy, but their use is associated with a distinct set of toxicities known as irAEs. Unlike traditional chemotherapy-induced toxicities, irAEs result from the overactivation of the immune system as it begins to attack not only cancer cells but also healthy tissues (26). These adverse events can affect almost any organ system, with the most commonly impacted being the skin, gastrointestinal tract, liver, and endocrine glands (27).

Dermatologic toxicities, such as rash and pruritus, are among the most frequent irAEs, often appearing early in treatment (28). Gastrointestinal irAEs, including colitis and diarrhea, can range from mild to severe, potentially leading to life-threatening complications if not promptly managed (29). Hepatotoxicity, manifesting as elevated liver enzymes or hepatitis, is another significant concern and requires careful monitoring and sometimes the cessation of ICI therapy (30). Endocrine irAEs, such as thyroiditis, adrenal insufficiency, and hypophysitis, can lead to long-term hormonal imbalances, necessitating ongoing hormone replacement therapy. Pulmonary toxicity, including pneumonitis, is less common but can be severe and life-threatening. Cardiovascular and neurological toxicities, though rare, can also occur and pose serious risks.

The management of irAEs often involves the use of corticosteroids and other immunosuppressants to mitigate the immune response (31). However, this approach can compromise the anti-tumor efficacy of ICIs, creating a delicate balance between controlling toxicity and maintaining therapeutic benefit. The unpredictability and potentially severe nature of irAEs underscore the need for close monitoring, early intervention, and the development of more selective ICIs that minimize off-target effects. As the use of ICIs continues to expand, understanding and managing these toxicities will be crucial for optimizing patient outcomes.

Biomarker-guided therapy represents a promising approach to enhancing the efficacy of ICIs by tailoring treatments to the unique characteristics of each patient’s tumor (32). Biomarkers such as PD-L1 expression, tumor mutational burden (TMB), and microsatellite instability (MSI) have been identified as potential predictors of response to ICIs. For example, high PD-L1 expression on tumor cells is often associated with a better response to PD-1/PD-L1 inhibitors, making it a critical factor in patient selection for these therapies. While high PD - L1 expression on tumor cells is often associated with a better response to PD - 1/PD - L1 inhibitors, it is acknowledged that other factors can also influence the efficacy of ICIs. For instance, the presence of immunosuppressive cells within the tumor microenvironment, such as regulatory Tregs and MDSCs, can dampen the immune response despite high PD - L1 expression (33). Additionally, genetic alterations within the tumor cells, like mutations in the interferon - gamma pathway genes, may affect the sensitivity of tumors to ICIs even in the presence of high PD - L1 levels (34). Therefore, a comprehensive evaluation that takes into account multiple factors is essential for accurate patient selection and treatment prediction.

Similarly, a high tumor mutational burden, which reflects the number of mutations within a tumor’s DNA, is correlated with increased neoantigen formation, potentially enhancing the immune system’s ability to recognize and attack the tumor (35). Microsatellite instability, a condition of genetic hypermutability, also serves as a biomarker for response to ICIs, particularly in colorectal cancers (36).

By utilizing these biomarkers, clinicians can more accurately identify patients who are most likely to benefit from ICI therapy, thus improving overall outcomes. Currently, there are ongoing efforts to standardize the assessment of biomarkers. Several professional organizations and research consortia are working towards establishing unified testing methods and criteria for biomarker evaluation. This includes standardizing the assays used to measure PD - L1 expression, TMB, and MSI, as well as defining cut - off values for determining biomarker positivity (37–39). Standardization is crucial as it would enhance the reproducibility and generalizability of biomarker - guided treatment strategies. If different laboratories and clinics use inconsistent methods, it could lead to varying results and inaccurate patient selection. With standardized assessment, the reliability of biomarker - based treatment decisions would improve, allowing for more effective implementation of personalized medicine in the context of ICIs. Furthermore, ongoing research is focused on discovering new biomarkers and refining existing ones, which could lead to even more personalized and effective treatment strategies in the future.

Combination therapies involving ICIs have emerged as a powerful strategy to enhance cancer treatment efficacy (40). By combining ICIs with other therapeutic modalities, such as chemotherapy, targeted therapy, radiotherapy, or even other ICIs, it is possible to overcome resistance mechanisms and achieve more robust and durable responses (41). The rationale behind these combinations lies in the synergistic effects that can be achieved when different treatments target complementary pathways involved in tumor growth and immune evasion.

For instance, chemotherapy and radiotherapy can induce immunogenic cell death, which increases the release of tumor antigens and enhances the subsequent immune response when paired with ICIs (42). Targeted therapies, such as those inhibiting angiogenesis or specific oncogenic pathways, can modify the tumor microenvironment, making it more susceptible to immune-mediated destruction. The combination of different ICIs, such as PD-1/PD-L1 inhibitors with CTLA-4 inhibitors, can simultaneously block multiple immune checkpoints, potentially leading to a more comprehensive activation of the immune system against the tumor.

Recent clinical trials have demonstrated the success of these combinations in various cancers, showing improved response rates and extended survival compared to monotherapy (43). However, combination therapies also pose challenges, including increased toxicity and the complexity of managing multiple treatments (44). Despite these challenges, the continued exploration of combination strategies holds significant promise for improving outcomes in patients who do not respond adequately to ICIs alone.

Optimizing the dosing and scheduling of ICIs is a critical strategy for maximizing their therapeutic efficacy while minimizing associated toxicities. Traditional dosing regimens often involve fixed doses or schedules that may not account for individual patient variability in drug metabolism and immune response (45). Emerging evidence suggests that alternative dosing strategies, such as intermittent dosing or dose reductions, can maintain anti-tumor efficacy while potentially reducing the risk of irAEs. These approaches could allow for better management of toxicities, making ICIs more tolerable for a broader range of patients, including those with comorbidities or lower tolerance for treatment.

In addition to dose optimization, adjusting the timing of ICI administration is also being explored as a way to enhance outcomes. For example, administering ICIs in conjunction with other treatments, such as chemotherapy or radiotherapy, at specific intervals may enhance the immune response by taking advantage of the immunomodulatory effects of these therapies (46). Similarly, the timing of ICI administration in relation to the patient’s circadian rhythms and immune cycles is an area of active research, with the potential to further refine treatment schedules for optimal results. These strategies represent promising avenues for improving the safety and effectiveness of ICI therapy.

Selective targeting and engineering of ICIs represent a promising approach to enhancing the specificity and safety of these therapies (47). Traditional ICIs, while effective, can lead to irAEs due to their broad activation of the immune system. To address this, researchers are developing next-generation ICIs that are designed to more precisely target tumor cells while sparing healthy tissues. One strategy involves engineering ICIs with enhanced affinity for tumor-specific antigens or altered immune checkpoint proteins that are predominantly expressed in the tumor microenvironment. This selective targeting reduces off-target effects and minimizes the risk of irAEs, potentially allowing for higher doses or more frequent administration without increasing toxicity (48).

In addition to improving selectivity, advances in protein engineering are enabling the creation of ICIs with optimized pharmacokinetics and pharmacodynamics (49). These engineered ICIs can be designed to have longer half-lives, greater stability, and more controlled activation, which enhances their efficacy and reduces the need for frequent dosing. Furthermore, bispecific antibodies that simultaneously target two immune checkpoints or combine checkpoint inhibition with other immune-stimulating functions are being explored as a way to increase the therapeutic potency of ICIs. These innovations are paving the way for more effective and safer cancer immunotherapies, offering new hope for patients who may not have benefited from existing treatments.

Immune modulation approaches aim to manage the irAEs associated with ICIs while preserving their therapeutic efficacy (50). One common strategy involves the use of corticosteroids and other immunosuppressive agents to dampen excessive immune responses that cause irAEs. However, this approach can sometimes blunt the anti-tumor effects of ICIs, creating a delicate balance between managing toxicity and maintaining the desired immune activation. Researchers are exploring alternative immune modulators that can more selectively target the pathways involved in irAEs without compromising the overall immune response against the tumor (51).

In addition to pharmacological interventions, immune modulation can also involve adjusting the timing or combination of ICIs with other therapies to modulate the immune response more effectively. For instance, combining ICIs with agents that promote regulatory T cells (Tregs) or other immune-regulating cells might reduce irAEs by controlling the extent of immune activation (52). These approaches are still in the early stages of research but hold promise for making ICI therapy safer and more tolerable, allowing more patients to benefit from these powerful cancer treatments without the burden of severe side effects.

Effective patient management and monitoring are critical components of optimizing immune checkpoint inhibitor (ICI) therapy. Given the potential for irAEs to affect multiple organ systems, early detection and intervention are essential to prevent severe complications. Routine monitoring of patients receiving ICIs should include regular assessments of symptoms, laboratory tests, and imaging studies to detect any emerging irAEs (53). Early identification allows for prompt management, which can include dose adjustments, temporary discontinuation of therapy, or the initiation of immunosuppressive treatments to control inflammation.

A multidisciplinary approach is often required to manage the diverse toxicities associated with ICIs. Involvement of specialists, such as endocrinologists, gastroenterologists, and pulmonologists, can help in the targeted management of specific irAEs (54). Additionally, patient education plays a crucial role in management, as patients need to be aware of the potential signs and symptoms of irAEs and the importance of reporting them promptly to their healthcare team. This proactive communication can lead to earlier interventions and better outcomes.

Long-term monitoring is also essential, as some irAEs may develop late in the course of treatment or even after therapy has ended. Continued follow-up ensures that any delayed toxicities are managed appropriately and that the overall health and quality of life of the patient are maintained. By integrating comprehensive monitoring protocols and a proactive management approach, clinicians can maximize the therapeutic benefits of ICIs while minimizing the risks, ultimately leading to improved patient outcomes in cancer therapy.

In this article, we explore various strategies aimed at enhancing the efficacy and reducing the toxicity of ICIs. These strategies, which include biomarker-guided therapy, combination therapies, optimizing dosing and scheduling, selective targeting and engineering of ICIs, immune modulation approaches, and comprehensive patient management, are summarized in Table 1 . This table provides a concise overview of the key approaches and their intended outcomes, illustrating the potential to improve both the safety and effectiveness of ICIs in cancer therapy.

In summary, ICIs have revolutionized cancer therapy, offering significant benefits but also presenting challenges such as variability in patient response and the risk of irAEs. Advances in biomarker-guided therapy, combination strategies, and the engineering of next-generation ICIs hold promise for overcoming these limitations. Ongoing research into optimizing dosing, patient management, and resistance mechanisms is crucial for enhancing the efficacy and safety of ICIs. By refining these strategies, ICIs can be more effectively integrated into personalized cancer treatment, improving outcomes for a broader range of patients.

The continued success of ICIs in cancer therapy hinges on the collaborative efforts of researchers, clinicians, and industry leaders. To fully realize the potential of ICIs, it is essential to prioritize research into understanding and overcoming resistance mechanisms, developing more precise biomarkers, and engineering next-generation ICIs with improved safety profiles. Clinicians must adopt a multidisciplinary approach to patient management, ensuring early detection and prompt intervention for irAEs. Additionally, there is a need for ongoing education and training to help healthcare professionals stay informed about the latest advancements in ICI therapy. By fostering innovation, collaboration, and education, the oncology community can enhance the effectiveness of ICIs, making these therapies more accessible and beneficial to a wider range of patients. The time to act is now, as the ongoing refinement of ICI strategies will be crucial in shaping the future of cancer treatment.

The advancements and refinements in immune checkpoint inhibitor (ICI) therapy are poised to significantly impact the future of cancer treatment. As we continue to develop more precise and personalized approaches, ICIs are likely to become integral components of combination therapies that target multiple aspects of tumor biology. The ongoing research into biomarkers and next-generation ICIs promises to expand their applicability to a broader range of cancers, including those previously resistant to treatment. Additionally, the improved management of irAEs will enable more patients to safely benefit from these therapies. These developments not only enhance the effectiveness of cancer treatment but also pave the way for new therapeutic paradigms that focus on long-term disease control and potentially curative outcomes. The future of cancer therapy will increasingly rely on the integration of ICIs into comprehensive, patient-specific treatment strategies that offer hope for better survival and quality of life.